Display options
Cite
Ji Y, Wu XB, Chen JY, et al. Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma. Int J Clin Exp Med. 2015;8(8):12850-7
Ji, Y., Wu, X. B., Chen, J. Y., Hu, B., Zhu, Q. K., Zhu, X. F., & Zheng, M. F. (2015). Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma. International journal of clinical and experimental medicine, 8(8), 12850-7.
Ji, Yong, et al. "Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma." International journal of clinical and experimental medicine vol. 8,8 (2015): 12850-7.
Ji Y, Wu XB, Chen JY, Hu B, Zhu QK, Zhu XF, Zheng MF. Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma. Int J Clin Exp Med. 2015 Aug 15;8(8):12850-7. eCollection 2015. PMID: 26550200; PMCID: PMC4612885.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Aug 15;8(8):12850-7. eCollection 2015.

Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma.

International journal of clinical and experimental medicine

Yong Ji, Xiao-Bo Wu, Jing-Yu Chen, Bin Hu, Qian-Kun Zhu, Xing-Feng Zhu, Min-Feng Zheng

Affiliations

  1. Department of Cardiothoracic Surgery, Wuxi People's Hospital Affiliated to Nanjing Medical University Wuxi 214023, China.

PMID: 26550200 PMCID: PMC4612885

Abstract

Patients with esophageal cancer are often diagnosed at advanced stages, leading to poor prognosis. Biomarkers are needed to enable earlier detection as well as to aid in the prediction of prognosis, but to date these tools remain scarce. Thymidine kinase (TK1) has been shown to exhibit altered expression levels in esophageal tumor cells, therefore this study sought to determine whether serum TK1 levels are also altered and, if so, to assess the utility of TK1 as a biomarker in esophageal squamous cell carcinoma. Eighty patients with esophageal squamous cell carcinoma were included as the case group and 80 healthy persons were selected as the control group. Serum TK1 levels, postoperatively for cancer patients, were detected by chemiluminescence. Follow-up was performed for cancer patients to determine the progression free survival (PFS) and overall survival (OS). Serum TK1 levels were significantly higher in cases of esophageal cancer than in healthy control individuals (t=7.235, P<0.05). When cancer cases were sub-divided into lower and higher serum TK1 levels, based on the mean level of 3.38 pmol/L, statistically significant differences in TNM stage, tumor differentiation, and lymph node metastasis were observed between patients with ≥3.38 pmol/L and <3.38 pmol/L (χ(2)=28.134, 3.187, 7.234, P<0.05). The average OS of all esophageal cancer patients was 30.13 months, and the average PFS was 24.73 months. However, when the cases were divided by serum TK1 level, average OS of those with higher serum TK1 (≥3.38 pmol/L) was significantly lower (23.98 mo) than those with lower serum TK1 (32.96 mo) (χ(2)=5.439, P<0.05). Similarly, average PFS was significantly lower in patients with higher serum TK1 (17.65 mo versus 27.62) (χ(2)=4.640, P<0.05). OS was correlated with TNM stage (hazard ratio, HR=3.116), degree of tumor differentiation (HR=0.427), lymph node metastasis (HR=0.535), and serum TK1 level (HR=1.913) (Wald χ(2)=6.782, 6.228, 4.562, 5.681, P<0.05). Similarly, PFS was correlated with TMN stage (HR=2.153), degree of tumor differentiation (HR=0.627), and serum TK1 level (HR=1.632) (Wald χ(2)=7.035, 5.335, 4.887, P<0.05). Thus, patients with esophageal squamous cell carcinoma exhibit higher circulating TK1 levels, consistent with findings of increased TK1 expression in tumor cells. Further, the correlation of serum TK1 levels with clinical features of esophageal cancer and with patient survival suggest that serum TK1 may serve as a valuable biomarker for predicting patient prognosis.

Keywords: Thymidine kinase 1; esophageal squamous cell carcinoma; prognosis; serological detection; survival analysis

References

  1. Eur J Cell Biol. 2009 Dec;88(12):779-85 - PubMed
  2. J Gastrointest Oncol. 2015 Feb;6(1):53-9 - PubMed
  3. Int J Clin Exp Med. 2014 Aug 15;7(8):2120-8 - PubMed
  4. J Clin Oncol. 2015 Jan 20;33(3):288-9 - PubMed
  5. Cell Res. 2004 Aug;14(4):295-302 - PubMed
  6. Semin Thorac Cardiovasc Surg. 2014 Summer;26(2):102-9 - PubMed
  7. Z Gastroenterol. 2015 Feb;53(2):115-9 - PubMed
  8. Int J Clin Exp Pathol. 2014 Oct 15;7(11):7663-71 - PubMed
  9. Anticancer Res. 2014 May;34(5):2145-51 - PubMed
  10. Hepatogastroenterology. 2014 Jul-Aug;61(133):1262-73 - PubMed
  11. Gut. 2013 Oct;62(10):1406-14 - PubMed
  12. Expert Opin Med Diagn. 2008 Feb;2(2):129-41 - PubMed
  13. World J Gastroenterol. 2013 Sep 14;19(34):5598-606 - PubMed
  14. Asian Pac J Cancer Prev. 2014;15(24):10981-4 - PubMed
  15. J Gastrointest Oncol. 2015 Feb;6(1):1-2 - PubMed
  16. Eur Radiol. 2014 Dec;24(12 ):3199-209 - PubMed
  17. Clin Endosc. 2015 Jan;48(1):70-3 - PubMed
  18. Mol Med Rep. 2008 Sep-Oct;1(5):705-11 - PubMed
  19. Vet Comp Oncol. 2012 Dec;10(4):292-302 - PubMed
  20. EMBO J. 2015 Feb 12;34(4):427-9 - PubMed
  21. Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):352-8 - PubMed
  22. Indian J Surg. 2014 Dec;76(6):494-503 - PubMed
  23. J Natl Compr Canc Netw. 2015 Feb;13(2):239-47 - PubMed
  24. Vojnosanit Pregl. 2014 Oct;71(10):975-7 - PubMed
  25. Lancet. 2013 Feb 2;381(9864):400-12 - PubMed
  26. J Thorac Oncol. 2014 Oct;9(10):1568-72 - PubMed

Publication Types